uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Farmaceutiska fakulteten, Institutionen för läkemedelskemi, Theranostics.
KTH Royal Inst Technol, Dept Prot Sci, Sch Engn Sci Chem Biotechnol & Hlth, Stockholm, Sweden.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för immunologi, genetik och patologi, Vaskulärbiologi.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Farmaceutiska fakulteten, Institutionen för läkemedelskemi, Theranostics.
Vise andre og tillknytning
2018 (engelsk)Inngår i: Theranostics, ISSN 1838-7640, E-ISSN 1838-7640, Vol. 8, nr 16, s. 4462-4476Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Vascular endothelial growth factor receptor-2 (VEGFR2) is a key mediator of angiogenesis and therefore a promising therapeutic target in malignancies including glioblastoma multiforme (GBM). Molecular imaging of VEGFR2 expression may enable patient stratification for antiangiogenic therapy. The goal of the current study was to evaluate the capacity of the novel anti-VEGFR2 biparatopic affibody conjugate (Z(VEGFR2)-Bp(2)) for in vivo visualization of VEGFR2 expression in GBM.

Methods: Z(VEGFR2)-Bp(2) coupled to a NODAGA chelator was generated and radiolabeled with indium-111. The VEGFR2-expressing murine endothelial cell line MS1 was used to evaluate in vitro binding specificity and affinity, cellular processing and targeting specificity in mice. Further tumor targeting was studied in vivo in GL261 glioblastoma orthotopic tumors. Experimental imaging was performed.

Results: [In-111]In-NODAGA-Z(VEGFR2)-Bp(2) bound specifically to VEGFR2 (K-D=33 +/- 18 pM). VEGFR2-mediated accumulation was observed in liver, spleen and lungs. The tumor-to-organ ratios 2 h post injection for mice bearing MS1 tumors were approximately 11 for blood, 15 for muscles and 78 for brain. Intracranial GL261 glioblastoma was visualized using SPECT/CT. The activity uptake in tumors was significantly higher than in normal brain tissue. The tumor-to-cerebellum ratios after injection of 4 mu g [In-111]In-NODAGA-Z(VEGFR2)-Bp(2) were significantly higher than the ratios observed for the 40 mu g injected dose and for the non-VEGFR2 binding size-matched conjugate, demonstrating target specificity. Microautoradiography of cryosectioned CNS tissue was in good agreement with the SPECT/CT images.

Conclusion: The anti-VEGFR2 affibody conjugate [In-111]In-NODAGA-Z(VEGFR2)-Bp(2) specifically targeted VEGFR2 in vivo and visualized its expression in a murine GBM orthotopic model. Tumor-to-blood ratios for [In-111]In-NODAGA-Z(VEGFR2)-Bp(2) were higher compared to other VEGFR2 imaging probes. [In-111]In-NODAGA-Z(VEGFR2)-Bp(2) appears to be a promising probe for in vivo noninvasive visualization of tumor angiogenesis in glioblastoma.

sted, utgiver, år, opplag, sider
IVYSPRING INT PUBL , 2018. Vol. 8, nr 16, s. 4462-4476
Emneord [en]
VEGFR2, affibody molecule, molecular imaging, SPECT, orthotopic glioma model, in vivo
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-365854DOI: 10.7150/thno.24395ISI: 000444104300013PubMedID: 30214632OAI: oai:DiVA.org:uu-365854DiVA, id: diva2:1263308
Forskningsfinansiär
Knut and Alice Wallenberg FoundationSwedish Research Council, 621-2012-5236Swedish Research Council, 2015-02509Swedish Research Council, 2015-02353VINNOVA, 2016-04060VINNOVA, 2017-02015Science for Life Laboratory - a national resource center for high-throughput molecular bioscienceSwedish Cancer Society, CAN2017/649Swedish Cancer Society, CAN2013/586Swedish Cancer Society, CAN2016/463Swedish Cancer Society, CAN2014/474Swedish Cancer Society, CAN2017/425Swedish Cancer Society, CAN2015/350Swedish Cancer Society, CAN2016/585
Merknad

De två första författarna delar förstaförfattarskapet.

De två sista författarna delar sistaförfattarskapet

Tilgjengelig fra: 2018-11-15 Laget: 2018-11-15 Sist oppdatert: 2018-11-15bibliografisk kontrollert

Open Access i DiVA

fulltext(1743 kB)88 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 1743 kBChecksum SHA-512
c1c240499eb8b289772e2b651b1e4f319410317ba35d6c5211d3ff8506254dcd4c867825031adf5ea5f62d77ea6119eee15ecaddef34364529cb7f855d20d0b8
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Mitran, BogdanRoche, Francis P.Lindström, ElinSelvaraju, RamkumarRinne, Sara S.Claesson-Welsh, LenaTolmachev, VladimirOrlova, Anna

Søk i DiVA

Av forfatter/redaktør
Mitran, BogdanRoche, Francis P.Lindström, ElinSelvaraju, RamkumarRinne, Sara S.Claesson-Welsh, LenaTolmachev, VladimirOrlova, Anna
Av organisasjonen
I samme tidsskrift
Theranostics

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 88 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 303 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf